Unapproved New Drugs/Misbranded: FDA Warning Letter to Med Shop Inc / www.medshopinc.com, 2026-06-23
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
Here's the summary: **FDA Warning Letter to Med Shop Inc (MARCS-CMS 725157, June 23, 2026)** The FDA Center for Drug Evaluation and Research issued a warning letter to Med Shop Inc / www.medshopinc.com, identifying violations of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and misbranded ketamine drug products into interstate commerce, including esketamine marketed as "Ketamine Nasal Spray" for treatment-resistant depression and chronic pain. The FDA states that while FDA-approved ketamine exists only as an injectable Schedule III controlled substance for anesthesia use, the website offers unapproved versions without the required drug application approval under section 505 of the FD&C Act, posing risks of contamination, incorrect dosing, and serious adverse events in the absence of medical supervision. The FDA requested that Med Shop Inc cease offering unapproved and misbranded drugs to U.S. consumers, warning that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: Med Shop Inc
**Company and Findings**
Med Shop Inc, operating through www.medshopinc.com, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on June 23, 2026. The agency documented that the Netherlands-based company was selling unapproved and misbranded ketamine products via the internet to U.S. consumers. FDA identified the violation during a website review on February 27, 2026. The agency emphasized particular concern about unapproved esketamine marketed as "Ketamine Nasal Spray," noting that while FDA-approved versions exist under brand names KETALAR and SPRAVATO, this company's product lacked approval. FDA stressed the serious risks posed by unapproved injectable drugs, including potential contamination, counterfeit ingredients, inconsistent dosing, and life-threatening complications like sepsis.
**Regulatory Citations**
The violations cite sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331, 352, 353, 355). Section 505(a) requires FDA approval before new drugs enter interstate commerce. Section 502(f)(1) requires adequate directions for use accessible to laypersons; prescription drugs cannot meet this standard by definition. Section 503(b)(1) designates drugs requiring practitioner supervision as prescription-only. These citations address both the legal approval pathway and labeling requirements that unapproved products inherently cannot satisfy.
**Next Steps and Monitoring**
Med Shop Inc must respond in writing within 15 business days to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov, detailing corrective actions and preventative measures. Compliance officers in pharmaceutical and e-commerce sectors should monitor whether the company ceases U.S. sales, implements website geofencing, or faces enforcement actions including seizure or injunction. The SPRAVATO REMS requirement—mandating certified healthcare settings and two-hour patient monitoring—underscores why unregulated distribution poses unacceptable public health risk.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Med Shop Inc / www.medshopinc.com MARCS-CMS 725157 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Med Shop Inc / www.medshopinc.com Netherlands info@medshopinc.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725157 To Med Shop Inc: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.medshopinc.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.medshopinc.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.medshopinc.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.medshopinc.com, FDA Establishment Identifier (FEI) 3043544193, on February 27, 2026. Violations of the Federal Food, Drug, and Cosmetic Act On your website at internet address w…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Med Shop Inc / www.medshopinc.com?
- FDA issued the letter (MARCS-CMS 725157) on 2026-06-23 and posted it publicly on fda.gov on 2026-07-07.
- Is the FDA warning letter to Med Shop Inc / www.medshopinc.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/med-shop-inc-wwwmedshopinccom-725157-06232026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Unapproved New Drugs/Misbranded: FDA Warning Letter to Med Shop Inc / www.medshopinc.com, 2026-06-23. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-med-shop-inc-www-medshopinc-com-2026-06-23-unapproved-drug
"Unapproved New Drugs/Misbranded: FDA Warning Letter to Med Shop Inc / www.medshopinc.com, 2026-06-23." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-med-shop-inc-www-medshopinc-com-2026-06-23-unapproved-drug.
Argus HQ Research. "Unapproved New Drugs/Misbranded: FDA Warning Letter to Med Shop Inc / www.medshopinc.com, 2026-06-23." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-med-shop-inc-www-medshopinc-com-2026-06-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_med_shop_inc_www_medshopinc_com_2026_06_23_unapproved_drug_2026,
title = {Unapproved New Drugs/Misbranded: FDA Warning Letter to Med Shop Inc / www.medshopinc.com, 2026-06-23},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-med-shop-inc-www-medshopinc-com-2026-06-23-unapproved-drug},
note = {Accessed: July 13, 2026}
}